The Role of Hydroxyurea in Enhancing the Virologic Control Achieved Through Structured Treatment Interruption in Primary HIV Infection: Final Results From a Randomized Clinical Trial (Pulse).
- Resource Type
- Article
- Authors
- Bloch, Mark T.; Smith, Don E.; Quan, Dick; Kaldor, John M.; Zaunders, John J.; Petoumenos, Kathy; Irvine, Kathy; Law, Matthew; Grey, Pat; Finlayson, Robert J.; McFarlane, Robert; Kelleher, Anthony D.; Carr, Andrew; Cooper, David A.
- Source
- JAIDS: Journal of Acquired Immune Deficiency Syndromes. 6/1/2006, Vol. 42 Issue 2, p192-202. 11p. 1 Diagram, 4 Charts, 7 Graphs.
- Subject
- *UREA
*ANTIRETROVIRAL agents
*COMBINATION drug therapy
*VIROLOGY
*HIV-positive persons
*HIV infections
*THERAPEUTICS
- Language
- ISSN
- 1525-4135
The article determines whether the addition of hydroxyurea in combination with antiretroviral (ARV) therapy including didanosine results in improved virologic control in the setting of structured treatment interruptions (STI) in patients with primary HIV infection (PHI). Success of the treatment was defined as maintaining viral loads at less than 5000 copies/ml for six months after ARV interruption. The study reveals that hydroxyurea was not found to be beneficial when used in association with STI in patients during PHI.